Himalaya Soon To Enter Cancer Therapy With Innovative Herbal Drugs

Herbal drugs pioneer Himalaya Drug Company is finally ready with its plans to be a serious player in the cancer therapy market worldwide. Backed by its well-known research strength in the natural science and Ayurveda, the company hopes to roll out at least five key drugs to fight out the alarmingly spreading disease.

The entry of Himalaya, the maker of Liv52 and Spetilin, into this serious therapy area has been keenly awaited as herbs or natural products-based oncology treatment is now widely relied as a better alternative to chemotherapy. The Bangalore-based company has been working on oncology targets in its research and development pipeline since 2003.

At Himalaya, researchers have been testing different herbal extracts to find the one that can stop the spread of cancer with no side effects. Its main focus has been on developing a herbal solution formulation that is safe and free from side effects. 

“We are at the final stages of the formulation development, including an expanded and multi-centric clinical studies, with some of our most promising natural compounds for oncology treatment now,” said Philipe Haydon, chief executive officer, Himalaya Drug Co., in an interview with BW Businessworld.

“And this is going to be an important and serious addition to our therapeutic focuses soon,” Haydon added. 

The company is expected to launch these anti-cancer products in the next three to four years. The oncology portfolio that Himalaya is currently planning to introduce in the market is believed to be much superior to the existing products available in the market in the given category. 

“Oncology is going to be another key therapeutic area that Himalaya is going to focus now and it will be strictly under the prescription channel as it is the case with all our pharma (herbal) products,” said T L Suresh, Business Head, Pharmaceutical Division, Himalaya Drug Co. 

“The innovation that we could bring into these products is definitely superior and these will have an edge over the existing treatments,” Suresh said.

The oncology products will come under its hospital sales division, which has about 200 field representatives at present. This division will be strengthened further with an addition of 300 people more once the oncology products are launched, Suresh added. 

Himalaya, which has some 4 lakh doctors in its coverage, has been steadily expanding its team of medical representatives in the last three to four years as it wants to increase the contribution from pharma division. The company, which has about 5000 medical representatives on its rolls, says that the team could go up to 10,000 people as it is planning to touch overall revenue of $1 billion by 2020.

The privately held company, which is currently present in some 90 markets globally with manly three areas of businesses, including pharmaceuticals, wellness and personal care and animal health, has also set an India target of $1 billion revenue by 2025. In order to expand the personal care business it has recently added baby and mother care segments and now plans to expand into male care and grooming too.



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Merck announces positive event-free survival data from phase 3 KEYNOTE-522 study of Keytruda to treat triple-negative breast cancer